SMC publishes an updated Collaborative Advice Document for COVID-19 medicines; update to the recommendations for nirmatrelvir plus ritonavir (update to TA878)

SMC has published an updated Collaborative Advice Document for COVID-19 medicines, which includes an update to the recommendations for nirmatrelvir plus ritonavir (Paxlovid). The recommendations are aligned with the updated NICE guidance for TA878 (01 May 2025).

A budget impact template is provided in confidence to NHS boards to enable them to estimate the predicted budget for medicines accepted for use. The updated template reflects the population now covered by the updated advice for nirmatrelvir plus ritonavir (Paxlovid).

You can find the NICE final guidance here: https://www.nice.org.uk/guidance/ta878